Characteristics of long-COVID among older adults: a cross-sectional study

Daitch, Vered; Yelin, Dana; Awwad, Muhammad; Guaraldi, Giovanni; Milić, Jovana V.; Mussini, Cristina; Falcone, Marco; Tiseo, Giusy; Carrozzi, Laura; Pistelli, Francesco; Nehme, Mayssam; Guessous, Idris; Kaiser, Laurent; Vetter, Pauline; Bordas-Martínez, Jaume; Durà-Miralles, Xavier; Peleato-Catalan, Dolores; Gudiol, Carlota; Shapira‐Lichter, Irit; Abecasis, Donna; Leibovici, Leonard; Yahav, Dafna; Margalit, Ili

doi:10.1016/j.ijid.2022.09.035

Cited by 48 publications

(33 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Taken together, our results contribute to further highlighting the importance of a follow-up for those subjects who experienced SARS-CoV-2 infection, with the aim to better identify patients at risk. In this context, we have noticed that age and female gender were independently associated with long COVID occurrence, confirming what has been already observed [ 16 , 17 ]. Of interest, we also reported that patients who developed long COVID more commonly experienced a hospital admission during acute SARS-CoV-2 infection.…”

Section: Discussionsupporting

confidence: 91%

“…In this large Italian cohort of COVID-19 patients, we reported an occurrence of long COVID in approximately 28% of cases, almost confirming most epidemiological available data [ 12 , 13 , 14 , 15 , 16 ]. Moreover, subjects affected by long COVID in our study population experienced a wide spectrum of symptoms, mainly dyspnea, fatigue and neuropsychiatric concerns that negatively affected quality of life, as previously described [ 12 , 13 , 14 , 15 , 16 ]. Taken together, our results contribute to further highlighting the importance of a follow-up for those subjects who experienced SARS-CoV-2 infection, with the aim to better identify patients at risk.…”

Section: Discussionsupporting

confidence: 87%

“…In this retrospective, propensity-score-matched case–control study, we have demonstrated for the first time that early therapy with mAbs or antivirals against acute SARS-CoV-2 infection is able to reduce the risk of occurrence of long COVID syndrome. Long COVID represents a broad and very heterogeneous clinical entity, with pathophysiological mechanisms which have not been fully elucidated and, consequently, have a lack of established therapies or prophylaxis [ 12 , 13 , 14 , 15 , 16 ]. In this large Italian cohort of COVID-19 patients, we reported an occurrence of long COVID in approximately 28% of cases, almost confirming most epidemiological available data [ 12 , 13 , 14 , 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…Long COVID represents a broad and very heterogeneous clinical entity, with pathophysiological mechanisms which have not been fully elucidated and, consequently, have a lack of established therapies or prophylaxis [ 12 , 13 , 14 , 15 , 16 ]. In this large Italian cohort of COVID-19 patients, we reported an occurrence of long COVID in approximately 28% of cases, almost confirming most epidemiological available data [ 12 , 13 , 14 , 15 , 16 ]. Moreover, subjects affected by long COVID in our study population experienced a wide spectrum of symptoms, mainly dyspnea, fatigue and neuropsychiatric concerns that negatively affected quality of life, as previously described [ 12 , 13 , 14 , 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study

Cimellaro

Addesi²,

Cavallo³

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Long COVID is a complex condition affecting quality of life, with limited therapeutic options. We investigated the occurrence of long COVID in subjects receiving early therapy with monoclonal antibodies (mAbs) or antivirals to reduce the risk of COVID-19 progression. In this retrospective study we enrolled 737 adult patients (aged 65.16 ± 13.46; 361F), who experienced COVID-19 between January 2021 and March 2022. Antiviral or mAbs were administered to symptomatic patients who did not require oxygen therapy or hospital admission for SARS-CoV-2 infection, and who were at high risk of progression to severe disease, as identified by age > 65 years or the presence of comorbidities. Long COVID, defined as newly or persistent long-term symptoms 4 weeks after the onset of the acute illness, was reported in 204 cases (28%). Age (OR 1.03; p < 0.001), gender (OR 1.88; p < 0.001) and at least three comorbidities (OR 3.49; p = 0.049) were directly associated with long COVID; conversely, vaccination (OR 0.59; p = 0.005) and mAbs/antivirals (OR 0.44; p = 0.002) were independently associated with a reduced risk of long COVID. At a propensity-score-matched analysis, the mAbs/antivirals group had a significantly lower occurrence of long COVID in comparison with untreated controls (11% vs. 34%; p = 0.001). In conclusion, mAbs and antivirals administered against the progression of COVID-19 were associated with a reduced risk of long COVID.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study

Cimellaro

Addesi²,

Cavallo³

et al. 2022

Biomedicines

View full text Add to dashboard Cite

show abstract

“…In other studies, additional risk factors described were age, hospital admission during acute infection, symptoms including dyspnea and chest pain, abnormal auscultation findings, and the presence of comorbidities such as asthma [ 12 , 13 , 14 ]. Furthermore, the presentation of this syndrome can vary depending on the risk factors and groups in question; for example, older individuals are already more likely to develop Long Covid; however, recent studies suggest that they have different persisting symptoms with more pronounced pulmonary impairment [ 15 ]. Robust population-based studies with appropriate control groups are required to identify biological risk factors specifically attributable to SARS-CoV-2 infection in both hospitalized and non-hospitalized individuals so that clinicians can better diagnose this evolving condition.…”

Section: Introductionmentioning

confidence: 99%

Long Covid: Untangling the Complex Syndrome and the Search for Therapeutics

Haque

Pant

2022

Viruses

View full text Add to dashboard Cite

Long Covid can affect anyone who has previously had acute COVID-19. The root causes of this syndrome are still unknown, and no effective therapeutics are available. This complex syndrome, with a wide array of symptoms, is still evolving. Given the dire situation, it is important to identify the causes of Long Covid and the changes occurring within the immune system of affected patients to figure out how to treat it. The immune system intersects with the persistent viral fragments and blood clots that are implicated in this syndrome; understanding how these complex systems interact may help in untangling the puzzling physiopathology of Long Covid and identifying mitigation measures to provide patients some relief. In this paper, we discuss evidence-based findings and formulate hypotheses on the mechanisms underlying Long Covid’s physiopathology and propose potential therapeutic options.

show abstract

Risk Factors Associated With Post−COVID-19 Condition

et al. 2023

View full text Add to dashboard Cite

ImportancePost−COVID-19 condition (PCC) is a complex heterogeneous disorder that has affected the lives of millions of people globally. Identification of potential risk factors to better understand who is at risk of developing PCC is important because it would allow for early and appropriate clinical support.ObjectiveTo evaluate the demographic characteristics and comorbidities that have been found to be associated with an increased risk of developing PCC.Data sourcesMedline and Embase databases were systematically searched from inception to December 5, 2022.Study SelectionThe meta-analysis included all published studies that investigated the risk factors and/or predictors of PCC in adult (≥18 years) patients.Data Extraction and SynthesisOdds ratios (ORs) for each risk factor were pooled from the selected studies. For each potential risk factor, the random-effects model was used to compare the risk of developing PCC between individuals with and without the risk factor. Data analyses were performed from December 5, 2022, to February 10, 2023.Main Outcomes and MeasuresThe risk factors for PCC included patient age; sex; body mass index, calculated as weight in kilograms divided by height in meters squared; smoking status; comorbidities, including anxiety and/or depression, asthma, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, immunosuppression, and ischemic heart disease; previous hospitalization or ICU (intensive care unit) admission with COVID-19; and previous vaccination against COVID-19.ResultsThe initial search yielded 5334 records of which 255 articles underwent full-text evaluation, which identified 41 articles and a total of 860 783 patients that were included. The findings of the meta-analysis showed that female sex (OR, 1.56; 95% CI, 1.41-1.73), age (OR, 1.21; 95% CI, 1.11-1.33), high BMI (OR, 1.15; 95% CI, 1.08-1.23), and smoking (OR, 1.10; 95% CI, 1.07-1.13) were associated with an increased risk of developing PCC. In addition, the presence of comorbidities and previous hospitalization or ICU admission were found to be associated with high risk of PCC (OR, 2.48; 95% CI, 1.97-3.13 and OR, 2.37; 95% CI, 2.18-2.56, respectively). Patients who had been vaccinated against COVID-19 with 2 doses had a significantly lower risk of developing PCC compared with patients who were not vaccinated (OR, 0.57; 95% CI, 0.43-0.76).Conclusions and RelevanceThis systematic review and meta-analysis demonstrated that certain demographic characteristics (eg, age and sex), comorbidities, and severe COVID-19 were associated with an increased risk of PCC, whereas vaccination had a protective role against developing PCC sequelae. These findings may enable a better understanding of who may develop PCC and provide additional evidence for the benefits of vaccination.Trial RegistrationPROSPERO Identifier: CRD42022381002

show abstract

Characteristics of long-COVID among older adults: a cross-sectional study

Cited by 48 publications

References 29 publications

Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study

Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study

Long Covid: Untangling the Complex Syndrome and the Search for Therapeutics

Risk Factors Associated With Post−COVID-19 Condition

Contact Info

Product

Resources

About